IL17A and neoplasm: IL-17 family members may serve as biomarkers in predicting the prognosis of the tumor and the therapeutic benefits of immune checkpoint inhibitors, considering that recent research has examined IL-17 in pan-cancer and has discovered that the expression of IL-17 family is variable in different tumors [107].